Selinexor (KPT-330) | Exportin 1 Inhibitor

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1393477-72-9
Formula :	C₁₇H₁₁F₆N₇O
M.W :	443.31
SMILES Code :	O=C(NNC1=NC=CN=C1)/C=C\N2N=C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)N=C2
Synonyms :	KPT-330; ATG-010
MDL No. :	MFCD27987944
InChI Key :	DEVSOMFAQLZNKR-RJRFIUFISA-N
Pubchem ID :	71481097

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

OCI-AML2	200 nM	48 h	To validate the activation of AKT signaling by Selinexor, results showed that Selinexor treatment significantly increased AKT phosphorylation.	PMC9949365
MOLM-13	75 nM	36 h	To validate the transcriptional upregulation of P2RY2 by Selinexor, results showed that Selinexor treatment significantly increased P2RY2 expression.	PMC9949365
AML cells	100 nM	16 h	To assess the drug-induced increase in mitochondrial apoptotic priming using Dynamic BH3 profiling to predict tumor cell response to therapy.	PMC4994896
WSU-FSCCL	100 nM	72 h	Selinexor combined with DEX or EVER significantly enhanced cytotoxicity in WSU-FSCCL cells	PMC5584550
WSU-DLCL2	100 nM	72 h	Selinexor combined with DEX or EVER significantly enhanced cytotoxicity in WSU-DLCL2 cells	PMC5584550
A2780-res1	0.2 μM	72 h	ERBB3 depletion restored the cytotoxic effect of KPT-185	PMC7415525
A2780-par	0.2 μM	72 h	Exogenous NRG1 reduced the cytotoxic effect of KPT-185	PMC7415525
Neuroblastoma cells	23.4–365.8 nM	72 h	To evaluate the cytotoxic effects of Selinexor on neuroblastoma cells, results showed that Selinexor induced cell death, and TP53 wild-type cells were more sensitive than mutant cells.	PMC8866064
P493-6 B cells	1μM	6 h	To evaluate the effect of XPO1 inhibition on MYC-induced replication stress, results showed that XPO1 inhibition increased DNA damage and caused G2-M phase cell cycle arrest.	PMC10758694
OCI-Ly1 cells	1μM	24 h	To evaluate the effect of XPO1 inhibition on the expression of DNA damage repair proteins, results showed that XPO1 inhibition reduced the expression of CHEK1, RAD51, and WEE1.	PMC10758694
OCI-AML2	200 nM	24 h	To validate selinexor’s ability to activate PI3K/AKT signaling, the results showed a significant increase in AKT phosphorylation after selinexor treatment.	PMC9949365
MOLM-13	75 nM	24 h	To validate selinexor’s ability to activate PI3K/AKT signaling, the results showed a significant increase in AKT phosphorylation after selinexor treatment.	PMC9949365
MV4;11	50 nM	24 h	To validate selinexor’s ability to activate PI3K/AKT signaling, the results showed a significant increase in AKT phosphorylation after selinexor treatment.	PMC9949365
HL-60	300 nM	24 h	To validate selinexor’s ability to activate PI3K/AKT signaling, the results showed a significant increase in AKT phosphorylation after selinexor treatment.	PMC9949365
OCI-AML3	250 nM	24 h	To validate selinexor’s ability to activate PI3K/AKT signaling, the results showed a significant increase in AKT phosphorylation after selinexor treatment.	PMC9949365
WiT49	100 nM	48 hours	Evaluate the effect of selinexor on cell cycle and apoptosis, showing decreased nuclear XPO1 levels and a marginal increase in p21	PMC9669237
KPMRT-NS	30 nM	6 and 24 hours	Evaluate the effect of selinexor on XPO1 activity, showing a significant decrease in XPO1 activity at 6 and 24 hours	PMC9669237
G401	30 nM	6 and 24 hours	Evaluate the effect of selinexor on XPO1 activity, showing a significant decrease in XPO1 activity at 24 hours	PMC9669237

Mice	MLL-AF9-driven AML model	Oral	15 mg/kg	Every other day for five cycles	To evaluate the efficacy of Selinexor combined with AKT inhibitor in AML mouse models, results showed that the combination therapy significantly prolonged survival.	PMC9949365
NSG mice	Patient-derived AML xenograft model	Oral	20 mg/kg	Three times a week for 4 weeks	To evaluate the antileukemic activity of Selinexor against AML cells, results showed that Selinexor significantly reduced the AML burden and was highly cytotoxic to leukemia-initiating cells (LICs).	PMC4994896
Mice	WSU-DLCL2 subcutaneous tumor model	Oral	10 mg/kg	Every other day for three weeks	Selinexor combined with DEX or EVER significantly inhibited tumor growth in the WSU-DLCL2 subcutaneous tumor model	PMC5584550
mice	A2780-res1 orthotopic ovarian cancer model	orally	20 mg/kg	twice weekly, until mice became moribund	ERBB3 depletion restored the anti-tumor effect of selinexor	PMC7415525
Mice	Neuroblastoma xenograft models	Oral	15 mg/kg	Twice weekly for 3 weeks	To evaluate the anti-tumor effects of Selinexor combined with Alisertib in neuroblastoma xenograft models, results showed that the combination therapy significantly inhibited tumor growth and induced tumor regression.	PMC8866064
NSG mice	Patient-derived tumor xenograft (PDTX) model	Oral	7.5 mg/kg	According to the dosing schedule shown in Fig. 3B	To evaluate the effect of XPO1 inhibition combined with CHOP on tumor growth, results showed that the combination significantly suppressed tumor growth and increased apoptosis.	PMC10758694
mice	MLL-AF9-driven AML model	oral	15 mg/kg	every other day for five weeks	To evaluate the efficacy of Selinexor combined with Ipatasertib in AML mouse models, the results showed that the combination significantly prolonged the survival of the mice.	PMC9949365
SCID mice	MDA-MB-468 xenograft model	Oral	5-25 mg/kg	Twice weekly or once weekly for 42 days	To evaluate the effect of KPT-330 on MDA-MB-468 xenograft model tumor growth, results showed that KPT-330 significantly inhibited tumor growth	PMC3954411

{[proInfo.proName]}

CAS No.: 1393477-72-9

{[proInfo.proName]}

CAS No.: 1393477-72-9

Alternative Products

Product Details of Selinexor

Safety of Selinexor

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT02078349	Solid Tumors	PHASE1	COMPLETED	2020-03-20	National University Hospital, ... More >>Singapore, 119228, Singapore Less <<
NCT02250885	Carcinoma, Neuroendocrine	PHASE2	COMPLETED	2025-08-16	Gabrail Cancer Center Research... More >>, Canton, Ohio, 44718, United States Less <<
NCT03944057	Relapse/Refractory Multiple My... More >>eloma Less <<	PHASE2	COMPLETED	2022-02-25	Beijing Chao-Yang Hospital, Ca... More >>pital Medical University, Beijing, Beijing, 100020, China\|Peking University Third Hospital, Beijing, Beijing, 100191, China\|Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, 510000, China\|Nanfang Hospital, Guangzhou, Guangdong, 510515, China\|Sun Yat-Sen University Cancer Center, Guanzhou, Guangdong, 510060, China\|Henan Cancer Hospital, Zhengzhou, Henan, 450003, China\|The Third Xiangya Hospital of Central Suoth University, Changsha, Hunan, 410013, China\|The First Affilate Hospital with Nanjing Medical University, Nanjing, Jiangsu, 210029, China\|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, China\|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China\|The First Bethune Hospital of Jilin University, Changchun, Jilin, 130021, China\|Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China\|Shanghai Changzheng Hospital, Shanghai, Shanghai, 200003, China\|Shanghai Sixth People's Hospital Affiliate Shanghai JiaoTong University, Shanghai, Shanghai, 200233, China\|Xijing Hospital, Xi'an, Shanxi, 710032, China\|Tianjin blood research institute, Tianjin, Tianjin, 300020, China\|The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China Less <<
NCT06552559	B-cell Lymphoma Recurrent\|B-ce... More >>ll Lymphoma Refractory\|CNS Metastases Less <<	PHASE1\|PHASE2	RECRUITING	2027-12-30	Samsung Cancer Research Instit... More >>ute, Seoul, 135-710, Korea, Republic of\|Samsung Medical Center, Seoul, 135-710, Korea, Republic of Less <<
NCT01607892	Hematological Malignancies	PHASE1	COMPLETED	2015-10-13	Moffitt Cancer Center, Tampa, ... More >>Florida, 33612, United States\|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States\|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States\|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States\|Weill Cornell Medical Center, New York, New York, 10065, United States\|Gabrail Cancer Center Research, Canton, Ohio, 44718, United States\|The Ohio State University, Columbus, Ohio, 43210, United States\|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States\|MD Anderson Cancer Center, Houston, Texas, 77030, United States\|Tom Baker Cancer Centre, Calgary, Alberta, T2W 4N2, Canada\|Princess Margaret Hospital, Toronto, Ontario, M5T 2M9, Canada\|Rigshospitalet, Copenhagen, 2100, Denmark Less <<
NCT02431351	Myelodysplastic Syndrome	PHASE2	WITHDRAWN	2025-05-19	-
NCT03627403	Primary Myelofibrosis\|Post-ess... More >>ential Thrombocythemia Myelofibrosis\|Post-polycythemia Vera Myelofibrosis Less <<	PHASE2	ACTIVE_NOT_RECRUITING	2025-03-14	Huntsman Cancer Institute/Univ... More >>ersity of Utah, Salt Lake City, Utah, 84112, United States Less <<
NCT02091245	Relapsed Acute Lymphoblastic L... More >>eukemia (ALL)\|Refractory Acute Lymphoblastic Leukemia (ALL)\|Relapsed Acute Myelogenous Leukemia (AML)\|Refractory Acute Myelogenous Leukemia (AML)\|Relapsed Mixed Lineage Leukemia\|Refractory Mixed Lineage Leukemia\|Relapsed Biphenotypic Leukemia\|Refractory Biphenotypic Leukemia\|Chronic Myelogenous Leukemia (CML) in Blast Crisis Less <<	PHASE1	ACTIVE_NOT_RECRUITING	2025-06-25	UCSF, San Francisco, Californi... More >>a, 94143, United States\|Children's Hospital Colorado, Aurora, Colorado, 80045, United States\|Children's Healthcare of Atlanta, Atlanta, Georgia, 30322, United States\|Boston Children's Hospital, Boston, Massachusetts, 02115, United States\|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States\|Columbia University Medical Center, New York, New York, 10032, United States\|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States\|Texas Children's Hospital, Houston, Texas, 77030, United States\|Seattle Children's Hospital, Seattle, Washington, 98101, United States\|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, 53226, United States Less <<
NCT05852028	Lymphoma\|DLBCL\|T Cell Lymphoma		RECRUITING	2025-10-18	Ruijin Hospital, Shanghai Jiao... More >> Tong University School of Medicine, Shanghai, Shanghai, 200025, China\|The First Affiliated Hospital of Soochow University, Suzhou, China\|Union Hospital Affiliated to Huazhong University of Science and Technology, Wuhan, China Less <<
NCT03466827	Thymoma\|Advanced Thymic Epithe... More >>lial Tumour Less <<	PHASE2	UNKNOWN	2020-07-01	Rigshospitalet, Copenhagen, 21... More >>00, Denmark\|Hospices Civils de Lyon, Lyon, France\|Intitut Curie, Paris, France\|Intitut Gustave Roussy, Paris, France Less <<
NCT04355676	Coronavirus Infection	PHASE2	WITHDRAWN	2020-08-30	-
NCT02146833	Prostate Cancer	PHASE2	TERMINATED	2016-04-01	M.D. Anderson Cancer Center, H... More >>ouston, Texas, 77030, United States Less <<
NCT05954780	Multiple Myeloma		RECRUITING	2026-09-15	Medizinische Universit?t Wien,... More >> Universit?tsklinik für Innere Medizin I, Wien, 1090, Austria\|Gemeinschaftspraxis für H?matologie und Onkologie GbR, Ravensburg, Baden-Württemberg, 88212, Germany Less <<
NCT05822050	PTCL Patients Who Achieved Com... More >>plete Response From Frontline Treatment Less <<	PHASE2\|PHASE3	RECRUITING	2025-06-30	The First Bethune Hospital of ... More >>Jilin University, Changchun, Jilin, 130021, China Less <<
NCT03850704	Multiple Myeloma		NO_LONGER_AVAILABLE	-	-
NCT02402764	Breast Cancer	PHASE2	COMPLETED	2019-06-06	H. Lee Moffitt Cancer Center a... More >>nd Research Institute, Tampa, Florida, 33612, United States Less <<
NCT06452446	Multiple Myeloma\|Large-cell Ly... More >>mphoma Less <<		NOT_YET_RECRUITING	2028-07-01	-
NCT02215161	Castration Levels of Testoster... More >>one\|Hormone-Resistant Prostate Cancer\|Metastatic Prostate Carcinoma in the Soft Tissue\|Prostate Carcinoma Metastatic in the Bone\|PSA Progression\|Stage IV Prostate Adenocarcinoma AJCC v7 Less <<	PHASE2	TERMINATED	2018-04-02	University of California, San ... More >>Francisco, San Francisco, California, 94115, United States Less <<
NCT05597345	Smoldering Multiple Myeloma	PHASE2	RECRUITING	2024-12-31	University of Rochester, Roche... More >>ster, New York, 14642, United States Less <<
NCT01986348	Glioblastoma\|Glioma	PHASE2	TERMINATED	2020-01-23	Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States\|Dana Farber Cancer Institute, Center for Neuro-Oncology, Boston, Massachusetts, 02215, United States\|Columbia University, Herbert Irving Comprehensive Cancer Center, New York, New York, 10032, United States\|The Phase I Unit, Dept. of Oncology, Rigshospitalet, Copenhagen, DK-2100, Denmark\|University of Groningen Faculty of Medical Sciences, Medical Oncology, Groningen, 9713 GZ, Netherlands\|Erasmus MC-Daniel den Hoed Cancer Center- Neuro-Oncology Unit, Rotterdam, 3008AE, Netherlands Less <<
NCT03147885	Diffuse Large B-Cell Lymphoma\|... More >>Recurrent B-Cell Non-Hodgkin Lymphoma\|Recurrent Extranodal Marginal Zone Lymphoma\|Recurrent Follicular Lymphoma\|Recurrent Indolent Adult Non-Hodgkin Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Waldenstrom Macroglobulinemia\|Refractory B-Cell Non-Hodgkin Lymphoma\|Refractory Extranodal Marginal Zone Lymphoma\|Refractory Follicular Lymphoma\|Refractory Mantle Cell Lymphoma\|Stage III Non-Hodgkin Lymphoma\|Stage IV Non-Hodgkin Lymphoma\|Transformed Recurrent Non-Hodgkin Lymphoma Less <<	PHASE1\|PHASE2	RECRUITING	2025-12-26	Barbara Ann Karmanos Cancer In... More >>stitute, Detroit, Michigan, 48201, United States Less <<
NCT05985161	Wilms Tumor\|Rhabdoid Tumor\|Mal... More >>ignant Peripheral Nerve Sheath Tumors\|MPNST\|Nephroblastoma\|XPO1 Gene Mutation\|Solid Tumor Less <<	PHASE2	RECRUITING	2029-08-01	Children's Hospital of Los Ang... More >>eles (Data Collection Only), Los Angeles, California, 90027, United States\|Children's Healthcare of Atlanta (Data Collection and Specimen Analysis), Atlanta, Georgia, 30322, United States\|Dana Farber Cancer Institute (Data Collection Only), Boston, Massachusetts, 02115, United States\|Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, 07920, United States\|Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, 07748, United States\|Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale, New Jersey, 07645, United States\|Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ), Commack, New York, 11725, United States\|Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, 10604, United States\|Memorial Sloan Kettering Cancer Center (All protocol activites), New York, New York, 10065, United States\|Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, 11553, United States\|Cincinnati Children's Hospital Medical Center (Data collection only), Cincinnati, Ohio, 45229, United States Less <<
NCT02025985	Ovarian Carcinoma\|Endometrial ... More >>Carcinoma\|Cervical Carcinoma Less <<	PHASE2	COMPLETED	2017-03-29	UZ Leuven - Universitair Zieke... More >>nhuis Leuven, Leuven, B-3000, Belgium\|Aalborg University Hospital, Aalborg, DK-9100, Denmark\|Rigshospitalet, Copenhagen, DK-2100, Denmark\|Herlev Hospital, Herlev, DK-2730, Denmark Less <<
NCT04595994	Sarcoma,Soft Tissue	PHASE1	RECRUITING	2026-05-31	Hospital de la Santa Creu i Sa... More >>nt Pau, Barcelona, 08025, Spain\|HU Vall d'Hebron, Barcelona, 08035, Spain\|H. Fundación Jiménez Díaz, Madrid, 28040, Spain\|Hospital Clínico San Carlos, Madrid, 28040, Spain\|Hospital Universitario La Paz, Madrid, 28046, Spain\|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain Less <<
NCT04811196	Soft Tissue Sarcoma\|Malignant ... More >>Peripheral Nerve Sheath Tumor (MPNST)\|Leiomyosarcoma\|Endometrial Stromal Sarcoma Less <<	PHASE1	ACTIVE_NOT_RECRUITING	2025-02-25	Princess Margaret Cancer Centr... More >>e, Toronto, Ontario, M5G 2M9, Canada Less <<
NCT02314247	Peripheral T-cell Lymphoma (PT... More >>CL)\|Cutaneous T-cell Lymphoma (CTCL) Less <<	PHASE2	TERMINATED	2025-02-16	Concord Repatriation General H... More >>ospital (CRGH), Concord, New South Wales, 2139, Australia\|Royal North Shore Hospital, St. Leonards, New South Wales, 2139, Australia\|Westmead Hospital, Westmead, New South Wales, 2145, Australia\|Cabrini Hospital, Malvern, Victoria, Australia\|National Cancer Centre, Singapore, 169610, Singapore Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed